CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 93 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $201,000 | -60.5% | 40,300 | 0.0% | 0.00% | – |
| Q4 2020 | $509,000 | +28.5% | 40,300 | 0.0% | 0.00% | – |
| Q3 2020 | $396,000 | -1.2% | 40,300 | 0.0% | 0.00% | – |
| Q2 2020 | $401,000 | +26.1% | 40,300 | +11.9% | 0.00% | – |
| Q1 2020 | $318,000 | -4.2% | 36,000 | 0.0% | 0.00% | – |
| Q4 2019 | $332,000 | +56.6% | 36,000 | 0.0% | 0.00% | – |
| Q3 2019 | $212,000 | -50.9% | 36,000 | 0.0% | 0.00% | – |
| Q2 2019 | $432,000 | +30.9% | 36,000 | +31.9% | 0.00% | – |
| Q1 2019 | $330,000 | +3.4% | 27,300 | +7.5% | 0.00% | – |
| Q4 2018 | $319,000 | -7.8% | 25,400 | +9.0% | 0.00% | – |
| Q3 2018 | $346,000 | -7.0% | 23,300 | +5.4% | 0.00% | – |
| Q2 2018 | $372,000 | -8.1% | 22,100 | +24.9% | 0.00% | – |
| Q1 2018 | $405,000 | +13.4% | 17,700 | +28.3% | 0.00% | – |
| Q4 2017 | $357,000 | +94.0% | 13,800 | +10.4% | 0.00% | – |
| Q3 2017 | $184,000 | +5.7% | 12,500 | 0.0% | 0.00% | – |
| Q2 2017 | $174,000 | – | 12,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 3,135,289 | $46,246,000 | 5.88% |
| GREAT POINT PARTNERS LLC | 2,006,211 | $29,592,000 | 5.76% |
| Lyon Street Capital, LLC | 463,064 | $6,830,000 | 2.63% |
| SENZAR ASSET MANAGEMENT, LLC | 335,445 | $4,948,000 | 1.21% |
| INGALLS & SNYDER LLC | 1,209,062 | $17,834,000 | 0.93% |
| Senvest Management, LLC | 314,629 | $4,641,000 | 0.31% |
| KNOTT DAVID M | 45,000 | $664,000 | 0.28% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 262,569 | $3,873,000 | 0.15% |
| PRINCETON CAPITAL MANAGEMENT INC | 14,607 | $215,000 | 0.11% |
| Manchester Capital Management LLC | 19,984 | $295,000 | 0.05% |